|Videos|August 6, 2016

Preventing Infection and Common Causes of VAC

Grace Lee, MD, MPH, associate medical director, Infection Control, Boston Children’s Hospital, discusses the current VAP bundle and its focus on infectious conditions as well as the need for a VAC bundle that will prevent other causes of VAC for patients on the ventilator.

Grace Lee, MD, MPH, associate medical director, Infection Control, Boston Children’s Hospital, discusses the current VAP bundle and its focus on infectious conditions as well as the need for a VAC bundle that will prevent other causes of VAC for patients on the ventilator.

Interview Transcript (slightly modified for readability).

“The current ventilator bundle, sometimes called the VAP bundle, targets infection, [such as] the prevention of pneumonia as a cause of ventilator-associated conditions on the vent. While that VAP bundle will be an important element of prevention, we understand that VAC is a much broader entity and that includes both infectious and noninfectious conditions. Because of that, we really need to think more broadly about a VAC prevention bundle.

Not only do we need to think about preventing infection, but we also need to think about how to prevent these other common causes of VAC for patients who are on the ventilator.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.